Metabolicly associated fatty liver disease. Practical recommendations of the Scientific Society of Gastroenterologists of Russia. Part 1

The proposed publication "Metabolic-associated fatty liver disease. Practical recommendations of the Scientific Society of Gastroenterologists of Russia" represents many years of work by a community of professionals aimed at improving the quality of treatment and diagnostic care for comorbid pathology, which is based on the concept of enterohepatocentrism developed by us. The material presented has already been largely presented in the form of separate articles in various issues of our journal, and the systematized materials will be published in a formalized form in subsequent issues of the journal. Part 1 is, in a certain sense, a report, presenting the names of oral reports that took place at the meetings of the Round Tables held over these two years. We draw the attention of colleagues to the lead article of this section "Targeted use of hepatoprotectors for the treatment of various stages of non-alcoholic fatty liver disease (fatty degeneration of the liver according to ICD 10) and associated comorbid conditions; tables for medical use”, which systematizes the latest data from national and international experience and is a logical continuation of the algorithm “Differentiated drug care for NAFLD-associated comorbidity”

NAFLD, metabolic syndrome, rational combinations, statins, fenofi brates, angiotensin- converting enzyme inhibitors, angiotensin II receptor blockers, sodium- dependent glucose transporter type 2 inhibitors, glucagon-like peptide-1 receptor agonists, resmetirom, ursodesoxycholic and glycerhisinic acids and their combinations, essential phospholipids, ademetionine, ornithine aspartate, taurine, human placental hydrolysate, morpholine, silymarin, artichoke leaf extract, metformin, pioglitazone, succinic acid